Latest news with #PaulArora
Yahoo
17-07-2025
- Business
- Yahoo
Fifty 1 Labs, Inc. (FITY) Sparks AI Breakthrough in Drug Repurposing: Subsidiary Fifty1 AI Labs Announces Strategic Partnership with Intent to Acquire BioSpark AI Technologies
SEATTLE, July 17, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, LLC, an innovative subsidiary of Fifty 1 Labs, Inc. (OTC: FITY), is thrilled to announce a strategic partnership with an intent to acquire BioSpark AI Technologies Inc., a Vancouver-based pioneer in advanced AI and large language model (LLM) technologies. Revealed today, this alliance is set to transform drug repurposing by leveraging cutting-edge AI to unlock transformative therapeutic insights from vast volumes of medical literature, advancing functional medicine and preventative care. Unleashing Hidden Insights with AI-Powered Precision This collaboration integrates BioSpark's proprietary AI and LLM platform with Fifty1 AI Labs' advanced predictive modeling to explore and organize extensive case-based medical literature. BioSpark's system automates the extraction, structuring, and indexing of real-world clinical data—covering patient journeys, treatment sequences, and outcomes—eliminating the inefficiencies of manual analysis. This empowers Fifty1 AI Labs to identify overlooked therapeutic patterns in longitudinal medical narratives, case series, and observational reports with unprecedented efficiency and scale. "Combining BioSpark's sophisticated insight engine with our predictive AI platform unlocks a wealth of untapped clinical knowledge," said Paul Arora, CEO of Fifty1 AI Labs. "This partnership, with our intent to acquire BioSpark, accelerates our ability to identify promising drug repurposing candidates, delivering innovative treatments to patients faster and solidifying our leadership in AI-powered functional medicine." A Synergistic Leap Toward Next-Generation Drug Repurposing By merging BioSpark's expertise in converting unstructured clinical data into structured, queryable formats with Fifty1 AI Labs' proprietary Bayesian inference and polypharmacy modeling, this partnership pioneers an advanced approach to drug repurposing, grounded in real-world clinical experiences and enhanced by AI-driven analytics. Fifty1 AI Labs will process, prioritize, and evaluate BioSpark-generated insights to streamline the transition from literature discoveries to clinical trials, focusing on high-potential sectors like performance health, chronic disease prevention, and wellness enhancement. This strategic alliance, with the intent to fully acquire BioSpark, strengthens Fifty1 AI Labs' visionary approach to dominating preventative healthcare through personalized, data-driven strategies and rapid candidate identification. It will fuel the development of repurposed formulations, incorporating proprietary transdermal and sublingual delivery systems optimized for superior patient outcomes. BioSpark's scalable literature mining capabilities will serve as a cornerstone in Fifty1's discovery and formulation processes. A Shared Vision for Human-AI Collaboration Bound by a shared commitment to enhancing human expertise with ethical, transparent AI tools, Fifty1 AI Labs and BioSpark AI Technologies aim to tap into the vast, often-overlooked potential within functional medicine that traditional clinical trials may miss. Through modern AI solutions, this partnership seeks to harness these opportunities securely, effectively, and at scale, while preserving researchers' intuitive judgment. "BioSpark's platform transforms complex clinical data into actionable knowledge for experts," said a BioSpark AI spokesperson. "Partnering with Fifty1 AI Labs, with their intent to acquire our technology, amplifies this impact, driving progress in functional medicine and drug repurposing through our shared vision for human-AI collaboration." About BioSpark AI Technologies Inc. Founded in 2022 in Vancouver, Canada, BioSpark AI Technologies Inc. specializes in organizing and integrating real-world clinical data using proprietary AI and LLM technologies. Holding a U.S. patent (US 20250029734 A1) for its AI system that automates patient journey extraction and structuring from unstructured medical literature, BioSpark enables scalable, precise automation for clinical development, outcomes research, and medical advancements. Learn more at About Fifty1 AI Labs, LLC Based in Seattle, Washington, Fifty1 AI Labs, LLC—a subsidiary of Fifty 1 Labs, Inc. (OTC: FITY)—is at the forefront of AI-driven functional medicine. Dedicated to transforming preventative healthcare and wellness, the company combines predictive AI with deep clinical insights to innovate in drug repurposing and formulation, addressing critical needs in performance health, chronic disease prevention, and personalized medicine. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's future financial and operating performance, business strategy, plans, objectives, expectations regarding future events or performance, and the potential acquisition of BioSpark AI Technologies Inc. These statements are based on current expectations, estimates, forecasts, and projections, and involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The company undertakes no obligation to update or revise any forward-looking statements, except as required by law. For additional details, refer to the company's filings with the Securities and Exchange Commission. Contact: Investor Relations Fifty 1 Labs, Inc. Email: ir@ Phone: (877) 505-5006 Website: Wire Service Contact: IBN Austin, Texas 512.354.7000 Office Editor@
Associated Press
07-02-2025
- Business
- Associated Press
Onco-Innovations Announces Expression of Interest Between Inka Health and Global Data Leader, Quantify Research
VANCOUVER, BC / ACCESS Newswire / February 6, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ('Onco' or the 'Company') is pleased to announce that its wholly-owned subsidiary, Inka Health Corp. ('Inka Health') has entered into an Expression of Interest (EOI) with Quantify Research ('Quantify'), a leading global provider of healthcare data analytics and real-world evidence solutions. This EOI establishes a framework for potential collaboration between the two entities to explore synergies in advanced data analytics and oncology research, with a particular focus on leveraging AI-driven predictive modelling to enhance cancer treatment insights. Quantify Research is a recognized leader in healthcare data analytics, specializing in health economics, outcomes research, and real-world evidence. With a decade of expertise in leveraging large Nordic and European healthcare data, Quantify provides critical insights to pharmaceutical companies, regulatory bodies, and healthcare institutions worldwide.1 Quantify, possessing unique access to high-quality real-world data (26 million+ patients with high coverage and lifetime follow up2) and expertise in RWD analytics, has expressed interest in collaborating with Inka Health to support the development of SynoGraph™ - Inka's proprietary platform designed to enhance precision medicine through causal graphical models parameterized in part with real-world data (RWD) - by providing analytical contributions and expertise in real-world data insights, including AI-powered predictive analytics to improve oncology treatment strategies. Under the terms of the EOI, Inka Health and Quantify Research intend to explore opportunities to collaborate on data-driven research initiatives, particularly supporting the development of SynoGraph™. Quantify Research has expressed interest in assisting Inka Health with refining, parameterizing, and validating SynoGraph™ models by providing access to a controlled environment with real-world data analytics, including structured data from electronic health records (EHR), claims data, genomics, imaging, and other relevant clinical metrics. All data access and processing will adhere to strict privacy and security measures to ensure compliance with applicable regulatory requirements. 'This Expression of Interest with Quantify Research is a pivotal step in exploring the integration of advanced real-world data analytics with our AI-driven SynoGraph platform. By combining our strengths, we aim to enhance precision medicine approaches in oncology and improve patient outcomes through data-driven insights,' stated Paul Arora, CEO of Inka Health. The EOI represents a strategic step for Onco-Innovations, towards advancing its mission of transforming cancer treatment research and drug development. By leveraging Quantify Research's expertise in real-world data analytics, Onco's wholly-owned subsidiary, Inka Health can work towards enhancing the development of its SynoGraph platform, with the aim of enabling more precise modelling and data-driven insights. Onco is actively exploring how to synergize SynoGraph's advanced analytical capabilities to support Onco's goal of refining oncology treatment strategies, identifying key biomarkers, and optimizing clinical trial designs. 'Aligning with Quantify Research supports our vision of leveraging AI and real-world data to drive innovation in oncology research,' said Thomas O'Shaughnessy, CEO of Onco-Innovations. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The Company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer. ON BEHALF OF ONCO-INNOVATIONS LIMITED, 'Thomas O'Shaughnessy' Chief Executive Officer For more information, please contact: Thomas O'Shaughnessy Chief Executive Officer Tel:+ 1 888 261 8055 The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release. Forward-Looking Statements Caution. This news release may contain forward-looking statements, including in relation to the EOI, the ability of the Company to realize synergies through its acquisition of Inka, the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'potential', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements, including as a result of there being no agreement or arrangement with Quantify beyond the EOI, or the failure of the Company to realize on the synergies and benefits expected from its acquisition of Inka. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. 1
